What is Amicus Therapeutics' stock symbol?
Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."
Where is Amicus Therapeutics' stock going? Where will Amicus Therapeutics' stock price be in 2017?
8 analysts have issued 1 year price objectives for Amicus Therapeutics' stock. Their forecasts range from $10.00 to $16.00. On average, they expect Amicus Therapeutics' stock price to reach $12.00 in the next twelve months.
When will Amicus Therapeutics announce their earnings?
Amicus Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, February, 24th 2017.
What are analysts saying about Amicus Therapeutics stock?
Here are some recent quotes from research analysts about Amicus Therapeutics stock:
According to Zacks Investment Research, "AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. " (1/9/2017)
Cowen and Company analysts commented, "FOLD announced interim Pompe Ph1/2 ATB200/AT2221 PK/PD data from the first 4." (12/8/2016)
Bank of America Corp analysts commented, "phase 2b data was encouraging" and "doctors indicate Zorblisa could have wide use," (5/18/2016)
Who owns Amicus Therapeutics stock?
Amicus Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Perceptive Advisors LLC (12.15%), Janus Capital Management LLC (4.84%), Palo Alto Investors LLC (4.50%), State Street Corp (4.02%) and Frazier Management LLC (1.83%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Daphne Quimi, Dipal Doshi, Donald J Hayden Jr, Ellen Rosenberg, Enrique Dilone, Glenn Sblendorio, Hung Do, Jay Barth, Jayne Gershkowitz, Jeff Castelli, John F Crowley, Julie Yu, Ken Valenzano, Kenneth Peist, Margaret G Mcglynn, Perceptive Advisors Llc and William D Baird III.
Who sold Amicus Therapeutics stock? Who is selling Amicus Therapeutics stock?
Amicus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Acuta Capital Partners LLC, Dimensional Fund Advisors LP, Franklin Resources Inc., Fred Alger Management Inc. and Metropolitan Life Insurance Co. NY. Company insiders that have sold Amicus Therapeutics stock in the last year include Daphne Quimi, Hung Do, Jay Barth, Perceptive Advisors Llc and William D Baird III.
Who bought Amicus Therapeutics stock? Who is buying Amicus Therapeutics stock?
Amicus Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Palo Alto Investors LLC, State Street Corp, Guggenheim Capital LLC, Tudor Investment Corp Et Al, FMR LLC and Brown Advisory Inc.. Company insiders that have bought Amicus Therapeutics stock in the last two years include Ellen Rosenberg, Margaret G Mcglynn and Perceptive Advisors Llc.
How do I buy Amicus Therapeutics stock?
Shares of Amicus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Amicus Therapeutics stock cost?
One share of Amicus Therapeutics stock can currently be purchased for approximately $6.27.